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Fig 1. Urticaria pigmentosa. Multiple round brownish
papules and macules on the legs.
Fig 2. Esophageal eosinophilia. Concentric linear furrows
on the esophageal mucosa.
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e208 Letterseosinophil-predominant infiltration is seen in
esophageal biopsy specimens.1,2 Various conditions
presenting esophageal eosinophilia, including
GERD, should be excluded. The present case could
not be diagnosed as EoE, because the patient had no
apparent symptoms of esophageal dysfunction,
although dense eosinophilic infiltration was seen in
the esophageal biopsy specimens and the
endoscopic features were consistent with EoE. The
patient had no other disorders that might cause
esophageal eosinophilia, and we cannot completely
exclude the possibility that the patient’s condition
will progress to EoE in the future.
Chemical mediators released from mast cells are
well known to induce eosinophilic infiltration.
TGF-1, which is expressed by both eosinophils
and mast cells, has been recognized as an important
molecular mediator of EoE.3 Abonia et al4 provided
evidence for the involvement of KIT ligand in the
pathogenesis of EoE. Niranjan et al5 reported
that mast cells play a critical role in muscular cell
hyperplasia and possibly in the esophagealOpen access under CC BY-NC-ND license.functional impairment of EoE. In this context, mast
cell infiltration in the esophagus and/or the skin may
have triggered the onset of esophageal eosinophilia
in the present case, although the mast cell infiltration
in the esophagus was sparse and the esophagus was
not apparently involved in the mastocytosis. The
present case might indicate an association between
UP and esophageal eosinophilia.
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Absence of HLA-DR1 positivity in 2 familial
cases of frontal fibrosing alopecia
To the Editor: Frontal fibrosing alopecia (FFA) is a
variant of lichen planopilaris (LPP), a specific
presentation of lichen planus involving the hair
follicles.1,2 HLA-DR1 positivity has already been
linked to cases of lichen planus and another variant
Fig 1. Familial frontal fibrosing alopecia. Side-by-side composite of patients 1 (left) and
2 (right).
Fig 2. Familial frontal fibrosing alopecia. Case 1. Peri-
follicular inflammation and lymphocytes within follicle.
(Hematoxylin-eosin stain; original magnification: 320.)
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in 2 related family members.3,4 To our knowledge,
only 1 reported case of familial FFA, another variant
of LPP, has been reported, and HLA-DR1 status in
that case was unknown, raising the question of
whether HLA-DR1 positivity correlates with FFA.5
We present 2 cases of familial FFA with negative
HLA-DR1 status.
Patient 1 was a 49-year-old Caucasian woman
who presented with an approximately 1.5 yeare
history of hair loss (Fig 1, left) refractory to topical
steroids. Physical examination was notable for
frontal and temporal scarring alopecia with
perifollicular erythemawith fine scales on her frontal
and temporal hairline. Thinning on the lateral
eyebrows was appreciated, but the eyelashes were
intact. The remainder of her scalp was unaffected. A
hair-pull test produced negative findings. Vellus hair
growth on bilateral axilla was noted. A scalp biopsy
specimen revealed perivascular and perifollicular
dermatitis with associated folliculitis (Fig 2). It
was notable for immunoglobulin heavy chain
monoclonality. T-cell receptor gene rearrangement
studies produced unremarkable results. An
antinuclear antibody multiplex screen and serum
protein electrophoresis revealed negative findings. A
complete blood count was notable for elevatedmonocytes (8.7%), and a comprehensive metabolic
panel produced unremarkable results, although a
slightly elevated aspartate aminotransferase was
noted (37 U/L [5-34]). An immunoglobulin panel
workup revealed a slightly elevated IgM (237 mg/dL
[40-230]). A bone-marrow biopsy specimen and
positron emission tomography/computed tomogra-
phy revealed unremarkable findings. HLA-DRB
typing revealed DRB1*04:XX,11:XX, DRB3: positive,
DRB4: positive, and DRB5: negative.
She had been scheduled to receive systemic
chemotherapy by her previous oncologist
because of the finding of monoclonality in the
immunoglobulin heavy chain rearrangement,
but chemotherapy plans were stopped after the
diagnosis of LPP.
Patient 2 was the 63-year-old Caucasian sister of
patient 1 with an approximately 2- to 3-year history
of hair loss involving her left temple and frontal
hairline (Fig 1, right) that had been refractory to
intralesional steroid injection and daily doxycycline.
Physical examination revealed scarring alopecia and
follicular erythema on the forehead and temporal
areas. She maintained terminal hair growth on the
axilla and groin areas. A scalp biopsy specimen
was compatible with LPP. A metabolic panel,
serum immunoglobulin panel, and serum protein
electrophoresis revealed unremarkable findings.
Her complete blood cell count was notable for
elevated monocytes (8.3%), and an antinuclear
antibody multiplex screen produced positive results.
HLA-DRB typing revealed the same findings as in
patient 1.
To date, only 1 other case of familial FFA has been
reported to our knowledge.5 We now report, to our
knowledge, the first case of familial FFA in the United
States and demonstrate that although HLA-DR1
positivity has been correlated with LPP and the
variant of LPP known as Lassueur-Graham-
LittleePiccardi syndrome, it does not appear to
correlate with the presence of FFA in our 2 familial
patients. Our case therefore raises the possibility that
other alleles may correspond with FFA.
Fig 1. Hidradenitis suppurativa. Facial nodular acne and
inflammatory subcutaneous nodules on the axillae
appeared in the setting of renal transplantation while the
patient was on cyclosporine.
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To the Editor: Hidradenitis suppurativa (HS) is a
chronic, recurrent inflammatory dermatosis involving
apocrine glandbearing skin, whose management
has no formal guidelines.1In November 2010, a 23-year-old Indian man
consulted for severe facial acne associated with
suppurating lesions of major body folds, which
had started 2 years after he underwent kidney
transplantation in 2007 for renal failure of unknown
origin. His immunosuppressive treatment included
cyclosporine (Cs) 150 mg/day and mycophenolate
mofetil 1.5 g/day. Treatment with isotretinoin
(20 mg/day) was introduced in April 2010 but led
to worsening of facial nodular acne. Subsequently,
inflammatory subcutaneous nodules developed on
